课题基金 / 基金详情

Developing powerful daisy drive systems for the precise alteration of local populations

Developing powerful daisy drive systems for the precise alteration of local populations
开发强大的雏菊驱动系统以精确改变当地人口
批准号:
10085329
负责人:
Kevin Esvelt
金额:
$16.29万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2022-06-30

项目摘要

项目成果

Kevin Esvelt的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary and Relevance Gene drive systems could solve ecological problems by altering entire populations of wild organisms. However, the self-sustaining nature of current CRISPR-based drive systems makes them likely to spread to most local populations, and very possibly to other populations of that species elsewhere in the world. Without a means of safe testing or securing international agreement prior to deployment, it is unclear how these types of gene drive systems can be ethically released. This proposal seeks to develop “daisy drive” systems capable of precisely and economically altering local populations of wild organisms. Specifically, the project will develop ways of reducing the fitness cost of both alteration and suppression drive systems, precisely controlling the extent to which they will spread, and perfectly reversing genetic changes spread by other types of CRISPR-based drive systems. By providing a path to community-supported, diplomatically feasible, and economical deployment, this proposal will facilitate the prevention of numerous vector-borne and parasitic diseases by spreading disease resistance among vectors or directly suppressing populations of disease agents. We anticipate that daisy drive interventions will serve as powerful weapons suitable for combating malaria, schistosomiasis, dengue, Zika, Lyme disease, and many more.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heritable immunization of the white-footed mouse reservoir of Lyme disease
Heritable immunization of the white-footed mouse reservoir of Lyme disease
Heritable immunization of the white-footed mouse reservoir of Lyme disease
EVOLVING VIRUS-SPECIFIC sACE2 MIMICS FOR COMPETITIVE INHIBITION OF SARS-CoV-2
海外基金